JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference - MSN

Among some of the top news at the conference were M&A deal announcements by J&J JNJ, Eli Lilly LLY and GSK GSK. While J&J announced a big deal to acquire neuroscience company …

$14
OFF

JNJ, GSK, LLY Announce M&A Deals At JP Morgan Conference

2 weeks from now

2 days ago · J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals. JNJ, GSK, LLY Announce M&A Deals at JP …

zacks.com

$15
OFF

Johnson & Johnson Makes $15 Billion Bet On Mental-health Drugs

2 weeks from now

3 days ago · Johnson & Johnson said it would pay $132 a share for Intra-Cellular. The stock closed at $94.87 a share on Friday. The deal is expected to be completed later this year and …

morningstar.com

$1.15
OFF

GSK Kicks Off M&A Push As Deal Speculation And Sunny Skies Set …

2 weeks from now

3 days ago · GSK will pay up to $1.15bn for IDRx, Lilly is said to be making a play for Scorpion, Biogen offered to buy Sage and Gilead announced a partnership with Leo Pharma ahead of …

citeline.com

$2
OFF

Lilly Circles $2.5B Scorpion Buy As Pre-JPM Rumour Mill Churns

2 weeks from now

6 days ago · A deal could be announced before the JPM conference begins Sunday in San Francisco. Scorpion's lead candidate, STX-478, is currently in Phase II testing and is an …

firstwordpharma.com

$1
OFF

JPM: GSK Announces $1.4bn Deal To Buy Asthma Biotech Aiolos

2 weeks from now

2 days ago · The deal – announced at the JP Morgan Healthcare conference this week – includes a sizeable $1 billion upfront payment, with up to $400 million more on the table if Aiolos’ …

pharmaphorum.com

$14
OFF

These Stocks Moved The Most Today: JPMorgan, Wells Fargo

2 weeks from now

19 hours ago · JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce …

yahoo.com

$2.68
OFF

GSK, J&J And Merck Drop Billions Of Dollars In M&A Deals To Start …

2 weeks from now

Jan 9, 2024 · The deal follows acquisitions — valued at a combined $2.68 billion — announced Monday by Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK), both North Jersey …

bizjournals.com

FAQs about JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference - MSN Coupon?

Which JP Morgan healthcare stocks have been featured in the blog?

Stocks recently featured in the blog include: J&J JNJ, Eli Lilly LLY, GSK GSK and Intra-Cellular Therapies ITCI. The JP Morgan Healthcare Conference, which is being held in San Francisco this year, has been much more active than last year. Among some of the top news at the conference were M&A deal announcements by J&J, Eli Lilly and GSK. ...

What happened at the JP Morgan Healthcare Conference?

The JP Morgan Healthcare Conference, which is being held in San Francisco this year, has been much more active than last year. Among some of the top news at the conference were M&A deal announcements by J&J JNJ, Eli Lilly LLY and GSK GSK. ...

Did J&J & Lilly buy intra-cellular therapies?

While J&J announced a big deal to acquire neuroscience company Intra-Cellular Therapies ITCI, Lilly and GSK announced smaller deals. The drug and medical devices giant entered into a definitive agreement to acquire Intra-Cellular Therapies for $132.00 per share or approximately $14.6 billion. ...

Is JP Morgan open for business on external innovation?

“I know a number of biotechs are in the room at this conference so it's worth mentioning: we're open for business on external innovation,” Ricks said at the J.P. Morgan Healthcare Conference Tuesday. Story ...

What is JP Morgan Healthcare Conference 2024?

With JP Morgan’s 42nd annual Healthcare Conference (JPM 2024) underway in San Francisco, biopharma companies worldwide are jumping at the opportunity to announce acquisition plans and business updates. ...

What will J&J's acquisition of intra-cellular therapies do?

The acquisition will add Intra-Cellular Therapies’ only approved drug, Caplyta, for the treatment of bipolar I and II depression and schizophrenia, to J&J’s neuroscience pipeline. ITCI has also filed a supplemental new drug application (sNDA) to the FDA seeking approval of Caplyta as an adjunctive treatment for major depressive disorder. ...